US-based medical device company Insulet and DexCom, a manufacturer of continuous glucose monitoring systems, have announced their intention to enable DexCom’s mobile App platform to integrate data from Insulet’s OmniPod system.
Currently, DexCom’s mobile App platform is under development. According to two companies, this will be the first version of a mobile App that is capable of incorporating glucose and other diabetes-related data from patients’ devices and displaying the integrated data via a smartphone App.
This event also marks the initiation of DexCom’s open architecture approach to diabetes-related data that will include an approved by DexCom indication to validate the authenticity of devices and Apps integrating DexCom continuous glucose monitoring data.
Insulet president and CEO Duane DeSisto said that providing OmniPod users and their healthcare providers with easier access to their management data is another key step in making diabetes a smaller part of life.
"Through DexCom’s mobile App platform, OmniPod users will have greater access to the data that is so essential for understanding and improving diabetes management," DeSisto added.
Insulet’s OmniPod is a tubeless insulin pump that has two parts and fully-automated cannula insertion.